257 related articles for article (PubMed ID: 20067471)
21. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
22. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
23. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
24. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
25. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects.
Lovejoy KS; Todd RC; Zhang S; McCormick MS; D'Aquino JA; Reardon JT; Sancar A; Giacomini KM; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Jul; 105(26):8902-7. PubMed ID: 18579768
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract][Full Text] [Related]
27. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Pestell KE; Hobbs SM; Titley JC; Kelland LR; Walton MI
Mol Pharmacol; 2000 Mar; 57(3):503-11. PubMed ID: 10692490
[TBL] [Abstract][Full Text] [Related]
28. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
Mellish KJ; Barnard CF; Murrer BA; Kelland LR
Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420
[TBL] [Abstract][Full Text] [Related]
29. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):29-38. PubMed ID: 10367746
[TBL] [Abstract][Full Text] [Related]
30. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
31. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
[TBL] [Abstract][Full Text] [Related]
32. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.
Chen Y; Zhang S; Sorani M; Giacomini KM
J Pharmacol Exp Ther; 2007 Aug; 322(2):695-700. PubMed ID: 17495125
[TBL] [Abstract][Full Text] [Related]
33. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
34. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
35. Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin.
Tummala R; Wolle D; Barwe SP; Sampson VB; Rajasekaran AK; Pendyala L
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1187-94. PubMed ID: 19322565
[TBL] [Abstract][Full Text] [Related]
36. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
Mellish KJ; Barnard CF; Kelland LR; Harrap KR
Int J Cancer; 1994 Oct; 59(1):65-70. PubMed ID: 7927906
[TBL] [Abstract][Full Text] [Related]
37. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
38. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
39. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.
Kurokawa T; He G; Siddik ZH
Cancer Chemother Pharmacol; 2010 Feb; 65(3):427-36. PubMed ID: 19529937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]